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Omics data miningMassive parallel DNA sequencing combined with chromatin immunoprecipitation and a large variety of DNA/
RNA-enrichment methodologies is at the origin of data resources of major importance. Indeed these resources,
available for multiple genomes, represent the most comprehensive catalogue of (i) cell, development and signal
transduction-speciﬁed patterns of binding sites for transcription factors (‘cistromes’) and for transcription and
chromatin modifying machineries and (ii) the patterns of speciﬁc local post-translational modiﬁcations of
histones and DNA (‘epigenome’) or of regulatory chromatin binding factors. In addition, (iii) the resources
specifying chromatin structure alterations are emerging. Importantly, these types of “omics” datasets populate
increasingly public repositories and provide highly valuable resources for the exploration of general principles
of cell function in a multi-dimensional genome–transcriptome–epigenome–chromatin structure context. How-
ever, data mining is critically dependent on the data quality, an issue that, surprisingly, is still largely ignored
by scientists andwell-ﬁnanced consortia, data repositories and scientiﬁc journals. Sowhat determines the quality
of ChIP-seq experiments and the datasets generated therefrom and what refrains scientists from associating
quality criteria to their data? In this ‘opinion’ we trace the various parameters that inﬂuence the quality of this
type of datasets, as well as the computational efforts that were made until now to qualify them. Moreover, we
describe a universal quality control (QC) certiﬁcation approach that provides a quality rating for ChIP-seq and
enrichment-related assays. The corresponding QC tool and a regularly updated database, from which at present
the quality parameters of more than 8000 datasets can be retrieved, are freely accessible at www.ngs-qc.org.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).With the release of the ﬁrst draft of the human genome in 2001 [1,2]
and the continued dramatic development of massive parallel sequencing
technologies, the race is open towards the analysis of genome
functions from a holistic point of view and a rapidly increasing fraction
of the medico-scientiﬁc community is getting engaged in this endeavor.
Notably, the combinationof high-throughputmassive parallel sequencing
technologywith amolecular biology technique termed chromatin immu-
noprecipitation (ChIP), which was ﬁrst described 30 years ago [3], pro-
vided an increasingly affordable high resolution approach to interrogate
protein interactions with entire genomes. In fact, in 2007 three publica-
tions described for the ﬁrst time the use of massive parallel sequencing
for global mapping of several factors to chromatin [4–6] and coined the
term “ChIP-seq” in analogy to the earlier ChIP-chip technology, which in-
volved the use of DNA microarray chips probed with ChIPed DNA [7].ra), hg@igbmc.u-strasbg.fr
. This is an open access article underIn the following seven years, more than 1300 publications related to
the term “ChIP-seq”were indexed inMEDLINE, covering a large range of
evaluated genome interactors, including not only transcription factors,
but also several post-translational modiﬁcations of histones (termed
histone ‘marks’), which together with DNA modiﬁcations deﬁne the
functional organization of the epigenome. In addition, a variety of
DNA/RNA-enrichment methodologies have been combined with mas-
sive parallel sequencing, which together with ChIP-seq assays, the
resulting datasets populate increasingly public repositories like the
Gene Expression Omnibus (GEO). Importantly, these resources are of
major interest as they represent the most comprehensive catalogue of
global protein–chromatin interaction, chromatin modiﬁcation patterns
and chromatin architecture for several genomes, inviting for genome-
wide multi-proﬁle comparisons in silico.
One of themajor challenges in the present “big data” era is to design
computational solutions that extract meaningful information from the
huge amounts of available data. In the “omics world” and more speciﬁ-
cally in the ChIP-seq and enrichment-related data resources, the aim isthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
1 The NGS-QC Quality Stamp is a simpliﬁed quality assessment that describes the qual-
ity of a proﬁle relative to the distribution of the QC indicators in the database. It is deﬁned
as QC-STAMP= denQCi(s50) / simQCi, where denQCi(s50) (or density quality control in-
dicator or QCi) is the fraction of genomic regions presenting a proportional decrease (un-
der deﬁned dispersion intervals) of their related read counts when 50% of total mapped
reads (TMRs) are used for proﬁle reconstruction and simQCi (or similarity QCi) corre-
sponds to the ratio between the denQCi computed for 90% TMRs over that computed for
50% TMRs. Intuitively, the higher the denQCi at 50% TMRs (s50) and lower the simQCi
(i.e. less difference between the denQCi at 90 and 50% TMRs), the higher the QC-STAMP
descriptor. Theproportional decrease is computed for threedispersion interval thresholds,
namely 2.5%, 5% and 10%; thus three QC-STAMP values are computed per evaluated pro-
ﬁle. As mentioned above, the comparison of these 3 QC-STAMPs with those computed
over the whole NGS-QC database provides a direct way to express the quality of a given
dataset relative to thewhole database. Speciﬁcally, the QC-STAMPs in the database are di-
vided into four quartiles, eachof them represented by a grade (fromA toD associatedwith
the upper to lower quartile respectively). Thus a dataset described as “AAA” presents each
of the 3 QC-STAMPs (2.5%, 5% and10% dispersion) as part of the upper quartile of the qual-
ity descriptors computed from the NGS-QC database.
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present in each studied proﬁle and (ii) to performmultiproﬁle compar-
isons in the context of their enrichment patterns to infer co-occurring
events that are the basis or consequence of, or linked to the biological
functions under study. In fact, since the release of the ﬁrst ChIP-seq
datasets, multiple computational solutions were developed for the
mapping of enrichment events in a conﬁdentmanner and several recent
studies focused on multiproﬁle comparisons (for a detailed review see
[8]). However, one of the pre-requisites for any comparison is that the
compared items are indeed comparable. Applied to ChIP-seq this
implies that only datasets of similar quality can be compared. But
what determines the quality of ChIP-seq experiments and the datasets
generated therefrom?
Assessing the quality of ChIP-seq datasets requires evaluation of the
performance of all involved steps— from the chromatin immunoprecip-
itation up to the construction of the sequencing library. In fact, while the
generally certiﬁed sequencing procedure itself is nowadays of very high
quality and reliability, the quality issues arise at the earlier steps of a
ChIP-seq procedure. Aspects like antibody speciﬁcity and sensitivity,
crosslinking and optimal chromatin fragmentation, number of PCR am-
pliﬁcation rounds applied during preparation of the sequencing library,
as well as the number of sequenced DNAmolecules (also referred to as
sequencing depth) per assay have a direct impact on the quality of the
generated dataset. While in principle each of these steps might follow
its own quality standards, there are important differences in the way
different laboratories handle the quality of antibodies or the minimal
sequencing depth required for generating optimal ChIP-seq datasets.
To address this issue, several recent studies have described different
types of qualitymetrics that would complement the visual inspection in
a genome browser - commonly performed as an intuitive way to evalu-
ate the quality of a ChIP-seq assay - with quantitative approaches.
Among them, the ENCODE consortium described recently guidelines
for ChIP-seq assays [9], which not only cover the experimental design
but also propose a certain number of computational metrics for the
evaluation of the quality of ChIP-seq generated datasets. However,
while these recommendations may be useful to improve the quality of
future datasets, each of these metrics has limitations, as discussed in
[10].
Overall, two major principle methodologies have been described to
generate such metrics, (i) those based on the use of peak caller algo-
rithms as initial read-outs and (ii) those assessing quality descriptors
in a peak caller-independent manner. The ﬁrst category corresponds
to methodologies which assess, for example, the Fraction of Reads in
Peaks [FRIP] [9] or the Irreproductibility Discovery Rate [IDR] [9,11]
from the comparative analysis of ChIP-seq replicates. In both cases the
need of using peak calling algorithms prior to quality evaluation is a
major drawback, as a large variety of peak calling methods perform
with high variability and in addition they operate with user-deﬁned pa-
rameters. Furthermore, depending on the nature of the enrichment type
(e.g., sharp binding events or broad enrichment patterns) different peak
callers are required for optimal identiﬁcation of enrichment patterns.
This makes it very difﬁcult, and frequently impossible to compare
such quality metrics when performing multiproﬁle comparisons.
Furthermore, the quality assessment by comparing ChIP-seq replicates
like that performed in IDR can only provide information about the
reproducible fraction of peaks shared between two replicate datasets,
but it will not distinguish per se the quality of the two individual
datasets. In addition, IDR is based on the availability of at least two repli-
cates per assay, which is generally suggested but (for cost reasons) often
not respected. This is conﬁrmed by our evaluation of available datasets in
the GEO repository. Finally, it is worth mentioning that a comparison of
multiple ChIP-seq replicates per deﬁnition reveals the degree of repro-
ducibility of identiﬁed enrichment events but reproducibility does not
automatically mean quality. For instance, multiple replicates produced
at suboptimal sequencing depths may suggest a low reproducibility,
albeit the corresponding chromatin immunoprecipitation may be ofhigh quality. In such cases combining all replicates in a single dataset
followed by sub-sampling of mapped reads (see below) could tell
whether the sequencing depth used accounts indeed for low pattern
reproducibility, or whether this is rather the consequence of a poor
ChIP assay.
As part of the second category, we could cite for instance the strand-
cross correlation approach [12] which computes the asymmetry
between forward and reverse strands. Importantly, while this approach
is applicable to proﬁles with sharp peaks, such as those seen for tran-
scription factors, it cannot be used for the broad proﬁles often seen for
histone marks. Thus, the absence of a general quality assessment for
the large amount of ChIP-seq datasets currently available in the public
domain, which allows their direct comparison, is a major handicap for
performing optimal multiproﬁle in silico data analysis.
With the aim of assessing quality descriptors in a peak-caller
independentmanner, we have developed a quality control (QC)metrics
applicable to any kind of dataset generated by massive parallel DNA
sequencing from ChIP-seq and other DNA/RNA enrichment-based
technologies [10]. Brieﬂy, this QC assessment compares the enrichment
patterns retrieved in a given proﬁle when only a fraction of the total
mapped reads is used for its reconstruction and provides local (i.e. relat-
ed to a deﬁned genomic region) and global (i.e. related to the whole
dataset) QC indicators, which for simplicity are also represented by a
3-letter acronymorQuality Stamps,1 similar to that used by credit rating
agencies (‘AAA’ for best quality datasets to ‘DDD’ for worst; see Fig. 1).
Without going into the details concerning its functionality, thismethod-
ology overcomes the above-described problems, making it a universal
approach for assessing and comparing the quality of enrichment-
based sequencing datasets. Note that the QC descriptors of more than
8000 publicly available datasets have been evaluated at present; we
are currently generating QC data for virtually all publicly available and
newly generated datasets using a fully automated procedure. This
certiﬁcation database (see Fig. 2 for a screenshot) is freely accessible
through a dedicated website (www.ngs-qc.org). This database is the
most comprehensive numerical QC collection for enrichment-based
NGS proﬁles and due to its “universal” application, it provides a solid
ground for multiproﬁle comparisons.
Publicly available ChIP-seq datasets have been generated from
platforms with a wide range of sequencing capacity, ranging from less
than 5 million sequenced reads in the early times of the ﬁrst Illumina
Genome Analysers to more than hundred million reads per dataset/
sample from a single lane when using the present sequencer genera-
tions. Despite this technological progress low quality datasets are still
retrieved at this point in time, arguing that inappropriate sequencing
depths have been chosen due to the possibility of saving costs by
multiplexing and/or that factors other than the sequencing depth are
causing bad performance (Fig. 3A). Nevertheless, as illustrated in
Fig. 3B, it is now possible to extract information about the minimal
sequencing depth that should be used for a given factor from the impor-
tant number of datasets available.
Fig. 1. Strategy applied by the NGS-QC Generator for assessing quality descriptors for ChIP-seq proﬁles. (A) Genome-browser screenshot illustrating three publicly available H3K4me3
ChIP-seq datasets. Based on a visual inspection we could conclude that, while all three proﬁles share common binding sites, important differences in their read count intensity levels as
well as in their background noise are observed. These datasets were subjected to the NGS-QC Generator pipeline for assessing quality descriptors. Brieﬂy, TMRs are randomly sampled
into three distinct populations (90, 70 and 50%), which are used for proﬁle reconstruction by computing the RCIs in 500-bp bins. The RCI divergence from expectation ismeasured relative
to the original proﬁle (s100). This information generates local quality indicators (QCis) and is displayed togetherwith the original RCI proﬁle to identify robust chromatin regions (local QCi
heat-map below the bottom proﬁles). In addition, global quality descriptors are computed which are summarized into the Global quality Grade or QC-STAMP. In this particular example,
the best H3K4me3 dataset received a “AAA” grade while the worst has been discerned a “DCC” QC-STAMP. It is worth to mention that the intuitive quality assessment performed by the
visual inspection is now comforted by a global and quantitative QC descriptor. (B) The NGS-QC Generator has been used to perform quality certiﬁcation of datasets retrieved in publicly
available repositories. Currently, more than 8000 datasets were certiﬁed covering a variety of data types andwere classiﬁed based on a quality score grades from AAA for the highest qual-
ity datasets to DDD for those presenting the worst, like input control datasets.
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Fig. 3. (A) NGS-QC certiﬁed datasets classiﬁed in the context of their repository submission dates. The illustrated violin plots are complemented by individual observations (green lines) to
enhance their density over different NGS-QC quality grades (grade borders are illustrated by red dashed lines). Note that input control datasets were excluded from this classiﬁcation to
avoid an artiﬁcial low quality bias. (B) Scatter-plot illustrating the correlation between the total mapped reads per analyzed H3K36me3 datasets and their quality indicator (NGS-QC
STAMP). Note that themajority of datasets presenting less than 15million TMRs are associated with quality grades “B”, “C” or “D”. In fact, quality “A” datasets are preferentially associated
to TMRs higher than 15 million reads.
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assays is the antibody used. Unfortunately, with the advent of the
‘omics’ generation, the commercial market for antibodies got swamped
with pseudo grades describing an antibody as “ChIP grade”, “ChIP-chip
grade” or “ChIP-seq” grade. While ChIP grades are generally accompa-
nied by quantitative real-time PCR assays to support this statement,
ChIP-chip and ChIP-seq grades are only supported by local enrichment
patterns displayed in genomic screenshots without providing quantita-
tive measure for such grading. In addition, some vendors support their
grading by making reference to a (prestigious) peer-reviewed publica-
tion where ChIP-seq or ChIP-chip assays have been performed with
this antibody, without considering whether that publication is based
on high or low quality enrichment patterns. It is clear that, despite the
existence of a set of quality descriptors, the use of the term “ChIP-seq
grade” is rather a marketing strategy than a real source of information.
Indeed, what is required is an independent QC assessment procedure
that applies deﬁned ChIP procedures and QC metrics to characterize
the performance of an antibody in ChIP-seq and related assays. At this
respect, it is worth to mention that the use of our methodology [10]
for assessing the quality of publicly available datasets allows extrapolat-
ing the performance of the antibodies in use and by consequence to
identify potential “ChIP-seq grade” antibodies this time by applying a
quantitative and independent certiﬁcation procedure.
In summary, the bad news is that despite the fast progress in the
‘omics’ ﬁeld still many low quality ChIP-seq and enrichment-based
datasets are generated and that there is no requirement to ascribe a
quality indicator to ChIP-seq datasets at publication. The good news is
that the large amount of datasets released in the public domain repre-
sents a highly valuable resource for mining the quality of the evaluated
datasets. We note, however, that unfortunately not all of the publicly
well-funded consortia provide access to their raw data, such that theirFig. 2. Screenshot (www.ngs-qc.org) of a search for ChIP-seq proﬁles for 5 targets (androgen r
ens”. A scatter plot (middle left) shows the different QC Stamps and indicates the quartiles (A, B
plot on the right reveals the corresponding range of QC Stamps for each target. Details of eac
displayed datasets are also available as a pop up window in our website (not shown) as well aquality can be evaluated, neither systematically associates to their pro-
ﬁles a given quality assessment. For this reason, we have developed the
NGS-QC system, which aids in extrapolating quality guidelines from
publicly available datasets and thereby hopefully inﬂuences the quality
of future datasets. Indeed, the NGS-QC descriptors represent for the ﬁrst
time a universal rating to classify datasets and antibodies.
It is very obvious from the NGS-QC database (www.ngs-qc.org) that
there is a large variation in the quality of ChIP-seq and other
enrichment-based NGS datasets. Several lines of arguments support
our view that future enrichment-based NGS datasets should be accom-
panied by quantitative QC metrics: (i) Given the investment in time,
effort and (public) costs of these assays, they deserve a quality stamp
that gives conﬁdence to other colleagues for using these datasets in
meta-analyses and considering them good enough to draw conclusions
in the context of their own studies; thisway unnecessary and costly rep-
etitions of the same assays can be minimized; (ii) currently it is nearly
impossible for editors, reviewers and readers of a study to assess the
quality of a ChIP-seq proﬁle, since screenshots do deﬁnitely not reveal
the quality of an entire ChIP-seq proﬁle. The addition of QC metrics to
a proﬁle will enhance both the conﬁdence in, and reproducibility of
the data; (iii) the development of novel types of epi-drugs and the in-
creasingly widespread use of enrichment-based NGS technologies in
drug development involves sooner or later the regulatory authorities
to request quality assessment metrics for these data. It is thus wise
that the scientiﬁc community adopts a generally applicable QC assess-
ment procedure and establishes guidelines that associates such metrics
with all published datasets; (iv) in the near future the development of
personalized medicine and the cost reductions from 4th generation
sequencing will result in a vast increase in the number of ‘omics’
datasets, including ChIP-seq and alike. The scientiﬁc community needs
to be prepared to distinguish high quality proﬁles from rubbish ineceptor, AR; H3K27ac; H3K4me1; H4K20me1; HDAC2) choosing as organism “Homo sapi-
, C, D) and the corresponding read depths using 10% divergence from expectance. The box-
h dataset are given at the bottom. In addition, Abstracts of associated publications to the
s a powerful search reﬁning panel. For details see the online manual and reference [10].
273M.A. Mendoza-Parra, H. Gronemeyer / Genomics Data 2 (2014) 268–273order to protect the consumer— the clinician/patient or any authorized
user who is generally not familiar with the interpretation of such large
datasets and the corresponding proﬁles.
Considering the importance of the quality assessment of enrichment-
based NGS datasets for the scientiﬁc community, the responsibility to-
wards granting institutions who invest enormous amounts of money in
a large number of consortia using these technologies, and to the public
that has the right to ask for an investment that generates highest quality
data, we propose that each dataset should be accompanied by a quality
assessment.We suggest that data repositories, such as GEO, and journals
ask for data quality assessment before they make new datasets publicly
available. The risk that we are facing is not only that low quality data
are ﬁlling up data repositories, which are or will be soon short of storage
space, but also that the extraction of highly valuable information from al-
ready existing datawill be precluded by their incomparability due to low
quality.
Conﬂict of interest
None declared.
Acknowledgments
Special thanks go to the bioinformaticians in the HG team, Pierre-
Etienne Cholley, Matthias Blum and Mohamed-Ashick M. Saleem, who
are continuously improving and updating the NGS-QC site, and to
SATT-Conectus Alsace for generously funding the NGS-QC project.
Studies in the laboratory of HG were supported by the AVIESAN-ITMO
Cancer, the Ligue National Contre le Cancer (HG; Equipe Labellisée)and the Institut National du Cancer (INCa). Support of the Agence
Nationale de la Recherche (ANRT-07-PCVI-0031-01, ANR-10-LABX-
0030-INRT and ANR-10-IDEX-0002-02) is acknowledged.References
[1] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, et al., Initial sequencing
and analysis of the human genome. Nature 409 (2001) 860–921.
[2] J.C. Venter, M.D. Adams, E.W. Myers, P.W. Li, R.J. Mural, et al., The sequence of the
human genome. Science 291 (2001) 1304–1351.
[3] D.S. Gilmour, J.T. Lis, Detecting protein–DNA interactions in vivo: distribution of
RNA polymerase on speciﬁc bacterial genes. Proc. Natl. Acad. Sci. U. S. A. 81
(1984) 4275–4279.
[4] A. Barski, S. Cuddapah, K. Cui, T.Y. Roh, D.E. Schones, et al., High-resolution proﬁling
of histone methylations in the human genome. Cell 129 (2007) 823–837.
[5] D.S. Johnson, A. Mortazavi, R.M. Myers, B. Wold, Genome-wide mapping of in vivo
protein–DNA interactions. Science 316 (2007) 1497–1502.
[6] T.S. Mikkelsen, M. Ku, D.B. Jaffe, B. Issac, E. Lieberman, et al., Genome-wide maps of
chromatin state in pluripotent and lineage-committed cells. Nature 448 (2007)
553–560.
[7] B. Ren, F. Robert, J.J. Wyrick, O. Aparicio, E.G. Jennings, et al., Genome-wide location
and function of DNA binding proteins. Science 290 (2000) 2306–2309.
[8] T. Bailey, P. Krajewski, I. Ladunga, C. Lefebvre, Q. Li, et al., Practical guidelines for the
comprehensive analysis of ChIP-seq data. PLoS Comput. Biol. 9 (2013) e1003326.
[9] S.G. Landt, G.K. Marinov, A. Kundaje, P. Kheradpour, F. Pauli, et al., ChIP-seq guide-
lines and practices of the ENCODE and modENCODE consortia. Genome Res. 22
(2012) 1813–1831.
[10] M.A. Mendoza-Parra, W. Van Gool, M.A. Mohamed Saleem, D.G. Ceschin, H.
Gronemeyer, A quality control system for proﬁles obtained by ChIP sequencing.
Nucleic Acids Res. 41 (2013) e196.
[11] Q. Li, J.B. Brown, H. Huang, P.J. Bickel, Measuring reproducibility of high-throughput
experiments. Ann. Appl. Stat. 5 (2011) 1752.
[12] G.K. Marinov, A. Kundaje, P.J. Park, B.J. Wold, Large-scale quality analysis of pub-
lished ChIP-seq data. G3 (Bethesda) 4 (2014) 209–223.
